Heuking advises TRUMPF Venture on EUR 13 million Series D funding round for iThera Medical
A team led by Dr. Hermann Ali Hinderer, Heuking Partner at the Stuttgart office, advised TRUMPF Venture II GmbH (“TRUMPF Venture”) legally and on matters of tax law in relation to closing a EUR 13 million Series D funding round of Munich-based medtech company iThera Medical GmbH (“iThera Medical”). In addition to TRUMPF Venture, existing investors such as Bayern Kapital participated again with funds from the Bavarian Growth Fund. Investments were also made by the EU Commission’s European Innovation Council Fund, Mey Capital Matrix, and Fluxunit. The company intends to use the proceeds from the funding to develop its proprietary diagnostics product optimized for routine clinical use and to secure regulatory approval in Europe and the U.S.
TRUMPF Venture is both a strategic partner and a corporate VC investor specializing in the promotion of promising startups in industry worldwide. Positioning itself as a long-term development partner, TRUMPF Venture typically seeks minority stakes ranging from 5% to 25%.
iThera Medical is a startup for optoacoustic imaging in medical diagnostics. One of the company’s new developments is MSOT (Multispectral Optoacoustic Tomography) technology, which allows the diagnosis of disease patterns such as cancer or fibrosis. It uses the conversion of light energy into sound waves to characterize, differentiate, and display different types of deep tissue in 3D images.
iThera Medical was founded as a spin-off of Helmholtz Center Munich in 2010.
Counsel to Trumpf Venture GmbH
Heuking Kühn Lüer Wojtek:
Dr. Hermann Ali Hinderer, LL.M. (Lead),
Anika Lisa Daschmann (both Private Equity / Venture Capital),
Antje Münch, LL.M. (IP), all Stuttgart,
Laura-Felicia Bokranz, LL.M. (University of Cape Town),
Christoph Hexel (both Employment), both Düsseldorf,
Cécile Corbet, LL.M. (Patent), Frankfurt,
Dr. Martin Schellenberg (Public Law),
Dr. Sarah Slavik-Schulz (Tax), both Hamburg